Arrakis Therapeutics
Cambridge, US · Founded 2015 · Delaware corporation · 8 known investors
Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease. Its pipeline includes a candidate for Type 1 Myotonic Dystrophy (DM1), a form of muscular dystrophy.
AI & Machine LearningBiotechDeep TechHealthtech
Founders & leadership
Arrakis Therapeutics was founded in 2015 by Michael Gilman and Mark DeLong.
MG
Michael GilmanCo-founder
MD
Mark DeLongCEO
DN
David NeafusExecutive
RC
Russell C. PetterExecutive
Board
CC%20copy.jpg)
AE
RP
CG
Carolyn GreenBoard director
Investors · 8
Canaan Partners✓ verifiedStamford · $500K – $20Mvia Colleen Cuffaro · board
Pfizer Ventures✓ verified
Advent Life SciencesLondonvia Alan Walts · board
Nextech InvestZurich · $648K – $3.2M
OUP (Osage University Partners)Bala Cynwyd · $1M – $20M
Pfizer Venture Investments$5M – $20M
venBio PartnersSan Francisco
Osage University PartnersreportedBala Cynwyd
Reported raises · per SEC filings
Form D private placements$28.2M disclosed across 2 rounds · 2017–2019
▶$15MraisedApr 2019 · 15 investors · BiotechnologyRule 506(b)
▶$15MraisedApr 2019 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nikola TrbovicDirector
- Raj ParekhDirector
- Michael GilmanExecutive Officer, Director
- Jakob LovenDirector
- Richard GasterDirector
- Colleen CuffaroDirector
- Offering amount
- $75M
- Amount sold
- $15M
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$13.2MraisedMar 2017 · 8 investors · BiotechnologyRule 506(b)
▶$13.2MraisedMar 2017 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Colleen CuffaroDirector
- Michael GilmanExecutive Officer, Director
- Carolyn GreenDirector
- Alan E. WaltsDirector
- David NeafusExecutive Officer
- Raj ParekhDirector
- Russell C. PetterExecutive Officer
- Offering amount
- $41.2M
- Amount sold
- $13.2M
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapBioworld32 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Aro Biotherapeutics28 shared keywordsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
Exelixis22 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Aclaris Therapeutics21 shared keywordsAclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases. The company's clinical and preclinical pipeline includes candidates in development for severe asthma, atopic dermatitis, and T-cell-mediated autoimmune conditions.
Companies competing with Arrakis Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Arrakis raises $8M for AI agent runtime securityruntimewire.com · Aug 2026Frequently asked questions
- What does Arrakis Therapeutics do?
- Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease. Its pipeline includes a candidate for Type 1 Myotonic Dystrophy (DM1), a form of muscular dystrophy.
- Who founded Arrakis Therapeutics?
- Arrakis Therapeutics was founded by Michael Gilman, Mark DeLong in 2015.
- Who are Arrakis Therapeutics's investors?
- Arrakis Therapeutics's investors include Canaan Partners, Pfizer Ventures, Advent Life Sciences, Nextech Invest, OUP (Osage University Partners), Pfizer Venture Investments, venBio Partners, Osage University Partners.
- How much funding has Arrakis Therapeutics raised?
- Arrakis Therapeutics has disclosed $28.2M raised across 2 rounds.
- Where is Arrakis Therapeutics headquartered?
- Arrakis Therapeutics is headquartered in Cambridge, US.